Lannett Adds NovoLog Biosimilar As It Writes Off $198m Of Value
Portfolio Rationalization Leads To 23 Product Discontinuations
Lannett has ambitions of $1bn of sales by 2025, driven by lucrative US opportunities like biosimilar insulins • Source: Shutterstock 
